array:19 [
  "pii" => "X0211699500025803"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:22-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2024
    "formatos" => array:3 [
      "EPUB" => 156
      "HTML" => 1556
      "PDF" => 312
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025799"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:24"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4016
      "formatos" => array:3 [
        "EPUB" => 165
        "HTML" => 3121
        "PDF" => 730
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Nefroangioesclerosis benigna como causa de insuficiencia renal crónica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "24"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. L. RODICIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. L. RODICIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025799?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025799/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025811"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:21"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1670
      "formatos" => array:3 [
        "EPUB" => 161
        "HTML" => 1253
        "PDF" => 256
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Déficit en la excrección de sobrecarga de sal, resistencia a la insulina y disfunción endotelial en la hipertensión"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "21"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C. FERNÁNDEZ-ANDRADE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "C. FERNÁNDEZ-ANDRADE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025811?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025811/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Role of Angiotensin Receptor Antagonists in the treatment of Hypertension, Heart Failure, and Renal Disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "22"
        "paginaFinal" => "23"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "C. M. FERRARIO , F.A.C.C."
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "C. M. FERRARIO , F.A.C.C."
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 Role of Angiotensin Receptor Antagonists in the treatment of Hypertension, Heart Failure, and Renal Disease C. M. Ferrario, MD, FACC Professor and Director. The Hypertension and Vascular Disease Center. Wake Forest University School of Medicine. Winston-Salem, North Carolina 27157. Clinical pharmacokinetics and metabolism studies show that losartan in an active, potent, and selective angiotensin II (Ang II) receptor blocker. It has a rapid and smooth onset on blood pressure, and is solely responsible for the beneficial antihypertensive effects on target organ damage. Losartan is converted to the active metabolite E3174 by the liver cytochrome P450 enzyme system. E-3174 exhibits significant biochemical activity and contributes to the duration of action as well as having a greater affinity for the AT1 receptor. Losartan, the active parent compound has a mean half-life of approximately 4-6 hrs. The active metabolite, E-3174, has a half-life exceeding 9 hrs. This dual antihypertensive action of both the parent compound and its metabolite may account for the prolonged and smooth blood pressure control observed in clinical trials and in the clinical experience gained in its worldwide application. Angiotensin II receptor blockers (ARBs) comprise a new class of antihypertensive agents whose action is mediated by prevention of binding of Ang II to the AT1 receptor. As an agent with indications for first line therapy of hypertension, ARBs controls blood pressure and retards Ang II related target organ damage. Within the family of therapeutic agents that antagonize the pathological actions of Ang II, ARBs differ from beta-blockers and angiotensin converting enzyme (ACE) inhibitors as illustrated in table 1. Clinically, the effects of ARBs are comparable to those obtained with ACE inhibitors, although additional long-term clinical studies are required to validate experimental conclusions. Nevertheless, the selective and specific action of ARBs in blocking the AT1 receptor affords a greater degree of specificity in preventing the pathological actions of Ang II. There are also opportunities to combine the beneficial aspects of ACE inhibitors and ARBs by the synergistic effect that is achieved from combining inhibition of Ang II formation and receptor activity. 22 Table I. Similarities and Differences Component Renin Activity Angiotensin I Converting Enzyme Angiotensin II -Blockers (-) (-/+) (-/+) (-) Angiotensin-(1-7) Kinins not determined (-/+) ACE Inhibitors (+++) (+++) (-) Acutely (-) Chronically (-/+) (+++) (+++) ARBs (++) (+) (-/+) (+) (++) (-) Keys: (-/+), no change&#59; (+), increase&#59; (-), inhibits. The assumption that ARBs may represent a single class of agents may require revision because there are differences in the action and effects between various receptor blockers. This is not unexpected since variations in the chemical structure of ARBs can have significant effects on their ability to bind to target organ receptors and access AT1 across the blood brain barrier or intracellularly. Tw o examples are illustrated. Losartan, the act i v e parent peptide has been observed to prod u c e a significant and sustained reduction in s e r u m uric acid, a factor associated with increa s e risk for cardiovascular disease and a troub l e s o m e co-morbid event in congestive heart f a i l u r e . Todate, other ARBs appear not to reduc e serum uric acid or augment urinary excret i o n of this factor. In animals, both losartan and E - 3 1 7 4 inhibit monocyte adhesion and act as c o m p e t i t i v e blockers of the thromboxane A 2 r e c e p t o r. Valsartan and candersartan, two other A n g II receptor blockers are weak antagonists at t h e thromboxane A 2 r e c e p t o r. T h u s , losartan and i t s active metabolite show additional beneficial a c t i o n s not shared by two other Ang II antago- ROLE OF ANGIOTENSIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF HYPERTENSION n i s t s : reversal of hyper-uricacidemia and antit h r o m b o t i c effects. In keeping with these observ a t i o n s , losartan has been shown to retard the d e v e l o p m e n t of atherosclerosis in a non-human p r i m a t e model by inhibiting monocyte recruitm e n t and retarding the oxidation of LDL. T h e s e d i f f e r e n t i a l effects among ARBs posits a quest i o n as to whether small changes in their chem i c a l and pharmacokinetic profile may be ass o c i a t e d with important differences in their a b i l i t y to block the pathological actions of Ang I I , independent of their effects on blood pressure. REFERENCES 1. Li P, Ferrario CM, Brosnihan KB: Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries J Pharmacol Exp Ther 281: 1065-1070, 1997. 2. Ferrario CM, Flack JM: Pathologic consequences of increased angiotensin II activity. Cardiovasc. Drugs Ther 10: 511-518, 1996. 3. Tallant EA, Ferrario CM: Drug evaluation: Cardiovascular & renal: Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs 5: 1-14, 1996. 4. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29: 634-640, 1997. 23 "
    "pdfFichero" => "P7-E170-S140-A1874.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025803/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025803/v0_201502091333/en/P7-E170-S140-A1874.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025803?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Role of Angiotensin Receptor Antagonists in the treatment of Hypertension, Heart Failure, and Renal Disease
C. M. FERRARIO , F.A.C.C.
Leído
5167
Veces
se ha leído el artículo
1773
Total PDF
3394
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699500025803"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:22-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2024
    "formatos" => array:3 [
      "EPUB" => 156
      "HTML" => 1556
      "PDF" => 312
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025799"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:24"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4016
      "formatos" => array:3 [
        "EPUB" => 165
        "HTML" => 3121
        "PDF" => 730
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Nefroangioesclerosis benigna como causa de insuficiencia renal crónica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "24"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. L. RODICIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. L. RODICIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025799?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025799/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025811"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:21"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1670
      "formatos" => array:3 [
        "EPUB" => 161
        "HTML" => 1253
        "PDF" => 256
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Déficit en la excrección de sobrecarga de sal, resistencia a la insulina y disfunción endotelial en la hipertensión"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "21"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "C. FERNÁNDEZ-ANDRADE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "C. FERNÁNDEZ-ANDRADE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025811?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025811/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Role of Angiotensin Receptor Antagonists in the treatment of Hypertension, Heart Failure, and Renal Disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "22"
        "paginaFinal" => "23"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "C. M. FERRARIO , F.A.C.C."
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "C. M. FERRARIO , F.A.C.C."
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 Role of Angiotensin Receptor Antagonists in the treatment of Hypertension, Heart Failure, and Renal Disease C. M. Ferrario, MD, FACC Professor and Director. The Hypertension and Vascular Disease Center. Wake Forest University School of Medicine. Winston-Salem, North Carolina 27157. Clinical pharmacokinetics and metabolism studies show that losartan in an active, potent, and selective angiotensin II (Ang II) receptor blocker. It has a rapid and smooth onset on blood pressure, and is solely responsible for the beneficial antihypertensive effects on target organ damage. Losartan is converted to the active metabolite E3174 by the liver cytochrome P450 enzyme system. E-3174 exhibits significant biochemical activity and contributes to the duration of action as well as having a greater affinity for the AT1 receptor. Losartan, the active parent compound has a mean half-life of approximately 4-6 hrs. The active metabolite, E-3174, has a half-life exceeding 9 hrs. This dual antihypertensive action of both the parent compound and its metabolite may account for the prolonged and smooth blood pressure control observed in clinical trials and in the clinical experience gained in its worldwide application. Angiotensin II receptor blockers (ARBs) comprise a new class of antihypertensive agents whose action is mediated by prevention of binding of Ang II to the AT1 receptor. As an agent with indications for first line therapy of hypertension, ARBs controls blood pressure and retards Ang II related target organ damage. Within the family of therapeutic agents that antagonize the pathological actions of Ang II, ARBs differ from beta-blockers and angiotensin converting enzyme (ACE) inhibitors as illustrated in table 1. Clinically, the effects of ARBs are comparable to those obtained with ACE inhibitors, although additional long-term clinical studies are required to validate experimental conclusions. Nevertheless, the selective and specific action of ARBs in blocking the AT1 receptor affords a greater degree of specificity in preventing the pathological actions of Ang II. There are also opportunities to combine the beneficial aspects of ACE inhibitors and ARBs by the synergistic effect that is achieved from combining inhibition of Ang II formation and receptor activity. 22 Table I. Similarities and Differences Component Renin Activity Angiotensin I Converting Enzyme Angiotensin II -Blockers (-) (-/+) (-/+) (-) Angiotensin-(1-7) Kinins not determined (-/+) ACE Inhibitors (+++) (+++) (-) Acutely (-) Chronically (-/+) (+++) (+++) ARBs (++) (+) (-/+) (+) (++) (-) Keys: (-/+), no change&#59; (+), increase&#59; (-), inhibits. The assumption that ARBs may represent a single class of agents may require revision because there are differences in the action and effects between various receptor blockers. This is not unexpected since variations in the chemical structure of ARBs can have significant effects on their ability to bind to target organ receptors and access AT1 across the blood brain barrier or intracellularly. Tw o examples are illustrated. Losartan, the act i v e parent peptide has been observed to prod u c e a significant and sustained reduction in s e r u m uric acid, a factor associated with increa s e risk for cardiovascular disease and a troub l e s o m e co-morbid event in congestive heart f a i l u r e . Todate, other ARBs appear not to reduc e serum uric acid or augment urinary excret i o n of this factor. In animals, both losartan and E - 3 1 7 4 inhibit monocyte adhesion and act as c o m p e t i t i v e blockers of the thromboxane A 2 r e c e p t o r. Valsartan and candersartan, two other A n g II receptor blockers are weak antagonists at t h e thromboxane A 2 r e c e p t o r. T h u s , losartan and i t s active metabolite show additional beneficial a c t i o n s not shared by two other Ang II antago- ROLE OF ANGIOTENSIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF HYPERTENSION n i s t s : reversal of hyper-uricacidemia and antit h r o m b o t i c effects. In keeping with these observ a t i o n s , losartan has been shown to retard the d e v e l o p m e n t of atherosclerosis in a non-human p r i m a t e model by inhibiting monocyte recruitm e n t and retarding the oxidation of LDL. T h e s e d i f f e r e n t i a l effects among ARBs posits a quest i o n as to whether small changes in their chem i c a l and pharmacokinetic profile may be ass o c i a t e d with important differences in their a b i l i t y to block the pathological actions of Ang I I , independent of their effects on blood pressure. REFERENCES 1. Li P, Ferrario CM, Brosnihan KB: Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries J Pharmacol Exp Ther 281: 1065-1070, 1997. 2. Ferrario CM, Flack JM: Pathologic consequences of increased angiotensin II activity. Cardiovasc. Drugs Ther 10: 511-518, 1996. 3. Tallant EA, Ferrario CM: Drug evaluation: Cardiovascular & renal: Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs 5: 1-14, 1996. 4. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29: 634-640, 1997. 23 "
    "pdfFichero" => "P7-E170-S140-A1874.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025803/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025803/v0_201502091333/en/P7-E170-S140-A1874.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025803?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 5 8 13
2024 Octubre 35 46 81
2024 Septiembre 47 40 87
2024 Agosto 56 49 105
2024 Julio 44 45 89
2024 Junio 44 40 84
2024 Mayo 60 47 107
2024 Abril 31 35 66
2024 Marzo 23 26 49
2024 Febrero 27 31 58
2024 Enero 23 28 51
2023 Diciembre 25 23 48
2023 Noviembre 23 27 50
2023 Octubre 24 24 48
2023 Septiembre 19 22 41
2023 Agosto 28 22 50
2023 Julio 31 31 62
2023 Junio 33 17 50
2023 Mayo 29 27 56
2023 Abril 14 16 30
2023 Marzo 24 19 43
2023 Febrero 21 21 42
2023 Enero 36 24 60
2022 Diciembre 31 20 51
2022 Noviembre 35 21 56
2022 Octubre 39 33 72
2022 Septiembre 33 33 66
2022 Agosto 28 28 56
2022 Julio 39 30 69
2022 Junio 48 31 79
2022 Mayo 39 21 60
2022 Abril 39 39 78
2022 Marzo 29 40 69
2022 Febrero 27 43 70
2022 Enero 37 31 68
2021 Diciembre 31 36 67
2021 Noviembre 39 33 72
2021 Octubre 40 40 80
2021 Septiembre 22 25 47
2021 Agosto 31 30 61
2021 Julio 34 29 63
2021 Junio 32 24 56
2021 Mayo 35 22 57
2021 Abril 61 47 108
2021 Marzo 37 13 50
2021 Febrero 61 10 71
2021 Enero 17 15 32
2020 Diciembre 21 7 28
2020 Noviembre 22 3 25
2020 Octubre 12 9 21
2020 Septiembre 16 6 22
2020 Agosto 23 4 27
2020 Julio 34 6 40
2020 Junio 40 17 57
2020 Mayo 24 12 36
2020 Abril 29 13 42
2020 Marzo 38 19 57
2020 Febrero 29 11 40
2020 Enero 51 10 61
2019 Diciembre 38 8 46
2019 Noviembre 52 8 60
2019 Octubre 32 8 40
2019 Septiembre 62 9 71
2019 Agosto 34 17 51
2019 Julio 25 10 35
2019 Junio 26 6 32
2019 Mayo 30 11 41
2019 Abril 49 30 79
2019 Marzo 20 11 31
2019 Febrero 11 12 23
2019 Enero 14 6 20
2018 Diciembre 29 25 54
2018 Noviembre 22 14 36
2018 Octubre 20 14 34
2018 Septiembre 14 8 22
2018 Agosto 25 11 36
2018 Julio 13 4 17
2018 Junio 16 11 27
2018 Mayo 14 6 20
2018 Abril 15 1 16
2018 Marzo 12 3 15
2018 Febrero 15 7 22
2018 Enero 12 4 16
2017 Diciembre 16 5 21
2017 Noviembre 11 6 17
2017 Octubre 16 3 19
2017 Septiembre 8 3 11
2017 Agosto 19 9 28
2017 Julio 14 3 17
2017 Junio 13 3 16
2017 Mayo 7 1 8
2017 Abril 11 2 13
2017 Marzo 13 1 14
2017 Febrero 4 2 6
2017 Enero 4 0 4
2016 Diciembre 22 3 25
2016 Noviembre 30 6 36
2016 Octubre 24 2 26
2016 Septiembre 41 1 42
2016 Agosto 74 0 74
2016 Julio 82 0 82
2016 Junio 58 0 58
2016 Mayo 67 0 67
2016 Abril 30 0 30
2016 Marzo 39 0 39
2016 Febrero 42 0 42
2016 Enero 29 0 29
2015 Diciembre 41 0 41
2015 Noviembre 35 0 35
2015 Octubre 27 0 27
2015 Septiembre 41 0 41
2015 Agosto 19 0 19
2015 Julio 24 0 24
2015 Junio 15 0 15
2015 Mayo 13 0 13
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?